News | September 09, 2025
Congruence gets $32 million financing to advance genetic obesity candidate drug
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Combination creates a leading, next generation claims operating system for payers, with end-to-end AI capabilities for claims, payments, care & utilization management, payment integrity, and member engagement, serving 115+ health plans
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
The three-day expo will feature an expansive exhibition showcasing MSMEs, startups, research institutions, future innovation pavilions, state showcases, and government initiatives
Fortis will assume complete operational and financial control, allowing it to consolidate the hospital's performance within its network
The hospital opens with 300 operational beds, including 100+ ICU beds and 5 advanced operating theatres
Subscribe To Our Newsletter & Stay Updated
